New website launched Our new website is here. Find out more

Paul GlueProfessor Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. Biomarkers for anxiety and the technical aspects of clinical trial design, including trialing simulation and modeling are other areas of interest. He has published extensively, with more than 300 papers, book chapters and abstracts to his name.

Find out more about Professor Paul Glue's research

Publications

Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., Glue, P., … Rodgers, A. (2023). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. British Journal of Psychiatry. Advance online publication. doi: 10.1192/bjp.2023.79
Journal - Research Article
Potiki, J., Tawaroa, D., Casey, H., Thom, K., O'Brien, A., Lenagh-Glue, J., & Glue, P. (2023). Cultural influences on the creation and use of psychiatric advance directives. Psychiatric Services. Advance online publication. doi: 10.1176/appi.ps.20220565
Journal - Research Article
Glue, P., & McNaughton, N. (2023). Why doesn't adjunctive ketamine enhance ECT's antidepressant efficacy in major depressive disorder: influence of ketamine dose. Psychiatry Research Case Reports. Advance online publication. doi: 10.1016/j.psycr.2023.100137
Journal - Research Article
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023). Ketamine and psychotherapy for the treatment of psychiatric disorders: Systematic review. BJPsych Open, 9, e79. doi: 10.1192/bjo.2023.53
Journal - Research Other
Lin, X. I., White, T., Gray, A. R., & Glue, P. (2023). The short- to medium-term predictive validity of the HoNOS-Secure on violence in a medium-secure forensic psychiatric ward in New Zealand. Journal of Forensic Psychiatry & Psychology, 34(2), 149-165. doi: 10.1080/14789949.2023.2189150
Journal - Research Article
De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. doi: 10.1016/B978-0-12-800213-1.00002-X
Chapter in Book - Research
Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.
Chapter in Book - Research
Barak, Y., Greco, P., & Glue, P. (2023). Aging among persons with serious mental illness: Policy implications for earlier onset of frailty. GeroPsyc, 36(2), 92-96. doi: 10.1024/1662-9647/a000302
Journal - Research Article
Glue, P., & McNaughton, N. (2023). Why doesn't adjunctive ketamine enhance ECT's antidepressant efficacy in major depressive disorder: influence of ketamine dose. Psychiatry Research Case Reports. Advance online publication. doi: 10.1016/j.psycr.2023.100137
Journal - Research Article
Lin, X. I., White, T., Gray, A. R., & Glue, P. (2023). The short- to medium-term predictive validity of the HoNOS-Secure on violence in a medium-secure forensic psychiatric ward in New Zealand. Journal of Forensic Psychiatry & Psychology, 34(2), 149-165. doi: 10.1080/14789949.2023.2189150
Journal - Research Article
Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., Glue, P., … Rodgers, A. (2023). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. British Journal of Psychiatry. Advance online publication. doi: 10.1192/bjp.2023.79
Journal - Research Article
Mentzel, C., Glue, P., Greco, P., & Barak, Y. (2023). Analysing realistic effects of modifiable risk factors for dementia in a large national dataset. Archives of Gerontology & Geriatrics, 105, 104852. doi: 10.1016/j.archger.2022.104852
Journal - Research Article
Potiki, J., Tawaroa, D., Casey, H., Thom, K., O'Brien, A., Lenagh-Glue, J., & Glue, P. (2023). Cultural influences on the creation and use of psychiatric advance directives. Psychiatric Services. Advance online publication. doi: 10.1176/appi.ps.20220565
Journal - Research Article
Stegmann, B., Gale, C., & Glue, P. (2023). Maintenance ECT treatment in New Zealand: Local and national data. Australasian Psychiatry, 31(1), 90-94. doi: 10.1177/10398562221126589
Journal - Research Article
Taube, C., Mentzel, C., Glue, P., & Barak, Y. (2023). Aging of persons with schizophrenia: Analysis of a national dataset. International Psychogeriatrics. Advance online publication. doi: 10.1017/S1041610223000145
Journal - Research Article
Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression. Clinical Pharmacology & Therapeutics. Advance online publication. doi: 10.1002/cpt.2640
Journal - Research Article
Bayes, A., Short, B., Zarate, C. A., Park, L., Murrough, J. W., McLoughlin, D. M., … Glue, P., … Loo, C. K. (2022). The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. Journal of Affective Disorders. Advance online publication. doi: 10.1016/j.jad.2022.04.020
Journal - Research Article
Goeldner, C., Kishnani, P. S., Skotko, B. G., Casero, J. L., Hipp, J. F., Derks, M., … and Clematis Study Group, including Glue, P. (2022). A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome. Journal of Neurodevelopmental Disorders, 14, 10. doi: 10.1186/s11689-022-09418-0
Journal - Research Article
Shadli, S. M., Delany, R. G., Glue, P., & McNaughton, N. (2022). Right frontal theta: Is it a response biomarker for ketamine's therapeutic action in anxiety disorders? Frontiers in Neuroscience, 16, 900105. doi: 10.3389/fnins.2022.900105
Journal - Research Article
Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2021). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience, 43, 253-261. doi: 10.1007/s11357-020-00285-y
Journal - Research Article
Barak, Y., Leitch, S., & Glue, P. (2021). The Great Escape: Centenarians' exceptional health. Aging Clinical & Experimental Research, 33(3), 513-520. doi: 10.1007/s40520-020-01552-w
Journal - Research Article
Neumann, S. R., Glue, P., & Linscott, R. J. (2021). Aberrant salience and reward processing: A comparison of measures in schizophrenia and anxiety. Psychological Medicine, 51, 1507-1515. doi: 10.1017/s0033291720000264
Journal - Research Article
Peng, M., Potterton, H., Chu, J. T. W., & Glue, P. (2021). Olfactory shifts linked to postpartum depression. Scientific Reports, 11(1), 14947. doi: 10.1038/s41598-021-94556-z
Journal - Research Article
Shadli, S. M., Ando, L. C., McIntosh, J., Lodhia, V., Russell, B. R., Kirk, I. J., Glue, P., & McNaughton, N. (2021). Right frontal anxiolytic-sensitive EEG 'theta' rhythm in the stop-signal task is a theory-based anxiety disorder biomarker. Scientific Reports, 11, 19746. doi: 10.1038/s41598-021-99374-x
Journal - Research Article
Stevenson, M. P., McEwan, J., Bentsen, P., Schilhab, T., Glue, P., Trani, P., Wheeler, B., & Healey, D. (2021). Nature walks versus medication: A pre-registered randomized-controlled trial in children with Attention Deficit/Hyperactivity Disorder. Journal of Environmental Psychology, 77, 101679. doi: 10.1016/j.jenvp.2021.101679
Journal - Research Article
Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2021). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology, 35(2), 137-141. doi: 10.1177/0269881120953991
Journal - Research Article
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 11. doi: 10.1177/20451253211056743
Journal - Research Article
Barak, Y., Cheung, G., Fortune, S., & Glue, P. (2020). No country for older men: Ageing male suicide in New Zealand. Australasian Psychiatry, 28(4), 383-385. doi: 10.1177/1039856220905304
Journal - Research Article
Barak, Y., Neehoff, S., & Glue, P. (2020). Ageing badly: Indicators of old-age structure in Australia and New Zealand. Journal of Primary Health Care, 12(3), 272-276. doi: 10.1071/hc19095
Journal - Research Article
Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474
Journal - Research Article
Back to top